| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0024 | 1 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.0026 | 1 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.0026 | 1 |